Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 7 of the 51 sources its claims cite were checked for support.
Abstract
Tuberous sclerosis is a single-gene disorder caused by heterozygous mutations in the TSC1 (9q34) or TSC2 (16p13.3) gene and is frequently associated with mental retardation, autism and epilepsy. Even individuals with tuberous sclerosis and a normal intelligence quotient (approximately 50%) are commonly affected with specific neuropsychological problems, including long-term and working memory deficits. Here we report that mice with a heterozygous, inactivating mutation in the Tsc2 gene (Tsc2(+/-) mice) show deficits in learning and memory. Cognitive deficits in Tsc2(+/-) mice emerged in the absence of neuropathology and seizures, demonstrating that other disease mechanisms are involved. We show that hyperactive hippocampal mammalian target of rapamycin (mTOR) signaling led to abnormal long-term potentiation in the CA1 region of the hippocampus and consequently to deficits in hippocampal-dependent learning. These deficits included impairments in two spatial learning tasks and in contextual discrimination. Notably, we show that a brief treatment with the mTOR inhibitor rapamycin in adult mice rescues not only the synaptic plasticity, but also the behavioral deficits in this animal model of tuberous sclerosis. The results presented here reveal a biological basis for some of the cognitive deficits associated with tuberous sclerosis, and they show that treatment with mTOR antagonists ameliorates cognitive dysfunction in a mouse model of this disorder.
Overview
CoChat Summary
TL;DR
Mice heterozygous for an inactivating *Tsc2* mutation show hippocampal-dependent learning and memory deficits in the absence of neuropathology or seizures, driven by hyperactive mTOR signaling that lowers the threshold for late-phase LTP. Brief rapamycin treatment in adult mice reversed both the synaptic plasticity abnormality and the behavioral deficits.
Key findings
- *Tsc2*+/− mice were impaired on three hippocampus-dependent tasks: Morris water maze probe trial (genotype × quadrant interaction *F*(3,88) = 4.763, *P* = 0.004; target crossings *F*(1,88) = 4.278, *P* = 0.0415), win-shift eight-arm radial maze across-phase errors (*F*(1,36) = 4.724, *P* = 0.0364), and context discrimination (mutants lacked context specificity). Hippocampus-independent visible-platform water maze and other behaviors (motor skills, anxiety, exploration, social approach) were normal.
- Hippocampal tuberin (Tsc2) abundance was reduced to ~75% of WT with unchanged hamartin (Tsc1), and phosphorylated S6 (Ser235/Ser236) was elevated, indicating disinhibited mTOR signaling.
- An E-LTP induction paradigm (1-s, 100-Hz tetanus) produced stable L-LTP in *Tsc2*+/− slices but decaying LTP in WT slices (measure × genotype interaction *F*(29,406) = 2.436, *P* < 0.0001; last 10 min *P* = 0.0328).
- Rapamycin reversed context discrimination deficits and water maze deficits in mutants (three-way ANOVA quadrant occupancy *F*(6,348) = 2.168, *P* = 0.0456; target crossings *F*(6,348) = 2.908, *P* = 0.0088) and reversed abnormal L-LTP; lovastatin did not rescue spatial learning. In *Tsc1*cc–αCaMKII-Cre mice, rapamycin increased survival to ~70% of Mendelian expectation, reduced brain enlargement (*P* < 0.001), and improved hindlimb clasping and ambulation (*P* < 0.001).
Methods
- Behavioral testing of *Tsc2*+/− mice (C57BL/6NCrl background, 3–6-month-old males and females) and conditional *Tsc1*cc–αCaMKII-Cre mice: hidden-platform Morris water maze (4 trials/day, 5 days, probe trial), win-shift eight-arm radial maze (8 daily sessions, 2-min delay), and context fear conditioning (three 0.75-mA shocks, tested in training vs. novel context).
- Acute hippocampal slice field recordings at Schaffer collateral–CA1 synapses (input-output, paired-pulse facilitation, LTP induced by theta burst or 1-s 100-Hz tetanus, recorded 4 h); western blots of hippocampal tuberin, hamartin, and p-S6.
- Rapamycin administered intraperitoneally (5 or 1 mg/kg daily, 3 h before training; 5 mg/kg for 5 days before fear conditioning), 200 nM in slice perfusate, or 0.2 mg/kg/day subcutaneously from postnatal day 1 in the *Tsc1* study; analyses by ANOVA and *t*-tests, *P* < 0.05 significant, experiments blind to genotype and treatment.
Limitations
- The paper states it is unclear whether rapamycin will reverse cognitive deficits caused by cerebral malformations or infantile spasms, and notes that genetic background may account for differences in social behavior between *Tsc1*+/− and *Tsc2*+/− mice and for variable expressivity of tuberous sclerosis phenotypes.
- Evident from the text: all evidence is from mouse models, so the proposed benefit of mTOR inhibitors for cognitive deficits in humans with tuberous sclerosis remains untested; the conditional *Tsc1*cc–αCaMKII-Cre analyses rest on very small surviving samples (e.g., *n* = 3 untreated and *n* = 4 rapamycin-treated mice for brain weight).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 0 Not valid · 27 Not checked · 75 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the *Tsc2*+/− mouse model, the *Tsc2* gene is disrupted by insertion of a selection cassette in its second coding exon[8](#R8).”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
What the sources say
- Supportedcites [8] Onda, H., Lueck, A., Marks, P.W., Warren, H.B. & Kwiatkowski, D.J. Tsc2+/− mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687–695 (1999). source
The Methods section 'Generation of mice with a targeted, disrupted Tsc2 gene' / 'Generation of a targeted Tsc2 allele in embryonic stem cells and mice' (p. 1 of that section) states the targeting construct was made by insertion of a neomycin resistance (Neo) selection cassette into the second coding exon of Tsc2, with clones selected using G418 and fialuridine. Passage [3] corroborates the disruption location ('As the gene was disrupted in the second coding exon'). (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Here we report that mice with a heterozygous, inactivating mutation in the *Tsc2* gene (*Tsc2*+/− mice)[8](#R8) show deficits in learning and memory.”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Abstract
What the sources say
- Supportedcites [8] Onda, H., Lueck, A., Marks, P.W., Warren, H.B. & Kwiatkowski, D.J. Tsc2+/− mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687–695 (1999). source
The citation follows the identification of the Tsc2+/− mice, while “Here we report” presents the learning-and-memory deficits as the citing authors’ own finding. In “Generation of mice with a targeted, disrupted Tsc2 gene,” the source describes producing mice heterozygous for an inactivated Tsc2 allele. It need not report the behavioral deficits to support this identification citation. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“a null mutation of the *Pten* gene caused some of the same phenotypes described for the *Tsc1*cc–αCaMKII-Cre mice”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 4.
What the sources say
- Supportedcites [21] Kwon, C.H., Zhu, X., Zhang, J. & Baker, S.J. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl. Acad. Sci. USA 100, 12923–12928 (2003). source
The introductory passage (page not provided) reports that neuron-specific Pten deletion caused seizures, premature death, and neuronal hypertrophy. The Results also report seizures and ataxia in adult Pten mutant mice. The comparison with Tsc1 mice is the citing authors’ framing; this source supports the attributed Pten phenotypes. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Brain enlargement was largely due to massive neuronal hypertrophy”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“this treatment reversed the context discrimination deficits of *Tsc2*+/− mice ([Fig. 3a](#F3)).”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 2.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
75 more claims
Create a free account to see all 109 claims and to verify the 7 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that tuberous sclerosis complex may be a result of the dysregulation of these processes13,69.”
From Activity-dependent neuronal signalling and autism spectrum disorder (2013) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar corrections with late-onset treatment in mice have been reported in tuberous sclerosis80 and spinocerebellar ataxia type 1 (SCA1)81.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [80]
The cited source says what the claim attributes to it.
In the citing paper
“Experimental interventions, working through diverse genetic and pharmacological mechanisms, rescue subsets of behavioral abnormalities in these mouse models (31, 43, 48–52).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [49]
The cited source says what the claim attributes to it.
In the citing paper
“Target strategies draw from therapeutics under investigation for other neurodevelopmental disorders and hypotheses emerging from mutations in synaptic genes identified in small numbers of individuals with autism spectrum disorders (43, 49, 52).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [49]
In the citing paper
“Ehninger et al. further demonstrated that abnormalities of LTP and deficiencies in hippocampal-dependent learning tasks in Tsc2+/- animals, in which mTOR-signaling is abnormally heightened, can be rescued by the mTOR inhibitor rapamycin.”
From Unifying Views of Autism Spectrum Disorders: A Consideration of Autoregulatory Feedback Loops (2016) · cites this paper as Ehninger et al., 2008
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
“three-way ANOVA for quadrant occupancy with genotype and treatment as between-subjects factors and pool quadrant as within-subjects factor”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
“genotype × treatment × quadrant interaction: *F*(6,348) = 2.168, *P* = 0.0456”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
“*n* = 12 mice per genotype; two-way ANOVA for quadrant occupancy with genotype as between-subjects factor and pool quadrant as within-subjects factor”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
“genotype × pool quadrant interaction: *F* (3,88) = 4.763, *P* = 0.004”
Citations
Cites
Hippocampus, space, and memory
Olton, D. S., Becker, J. T., & Handelmann, G. E. (1979) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00062713 · Cited by 2,018
Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34
Slegtenhorst, M. V., Hoogt, R. D., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., Ouweland, A. V. D., Halley, D., Young, J., et al. (1997) · Science · doi:10.1126/science.277.5327.805 · Cited by 1,648
Self-citationIdentification and characterization of the tuberous sclerosis gene on chromosome 16
(1993) · Cell · doi:10.1016/0092-8674(93)90618-z · Cited by 1,645
Tang, S. J., Reis, G., Kang, H., Gingras, A.-C., Sonenberg, N., & Schuman, E. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012605299 · Cited by 734
Kwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 667 · cited 1×
“To test the efficacy of rapamycin in modulating other tuberous sclerosis brain phenotypes, we studied a homozygous conditional deletion of Tsc1 in neurons of the postnatal forebrain: floxed Tsc1 mice ( Tsc1 cc”
BackgroundSelf-citationFloresco, S. B., Seamans, J. K., & Phillips, A. G. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01880.1997 · Cited by 626 · cited 1×
“, and because the hippocampus can contribute to working memor”
BackgroundRegulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2
Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J., & Sabatini, B. L. (2005) · Nature Neuroscience · doi:10.1038/nn1566 · Cited by 497 · cited 1×
“Second, Tsc1 −/− hippocampal neurons were shown to have morphological and functional synaptic abnormalitie”
BackgroundSelf-citationSancak, O., Nellist, M., Goedbloed, M., Elfferich, P., Wouters, C., Maat-Kievit, A., Zonnenberg, B., Verhoef, S., Halley, D., & van den Ouweland, A. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201402 · Cited by 483
The dorsal hippocampus is essential for context discrimination but not for contextual conditioning.
Frankland, P. W., Cestari, V., Filipkowski, R. K., McDonald, R. J., & Silva, A. J. (1998) · Behavioral Neuroscience · doi:10.1037//0735-7044.112.4.863 · Cited by 410 · cited 1×
“Discriminating between similar contexts is known to also depend on hippocampal functio”
BackgroundSelf-citationOnda, H., Lueck, A., Marks, P. W., Warren, H. B., & Kwiatkowski, D. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7319 · Cited by 349
Self-citation
Cited by
Items 401–500 of 860
Fruit flies and intellectual disability
Bolduc, F. V., & Tully, T. (2009) · Fly · doi:10.4161/fly.3.1.7812 · Cited by 38
Neuroligins Provide Molecular Links Between Syndromic and Nonsyndromic Autism
Singh, S. K., & Eroğlu, Ç. (2013) · Science Signaling · doi:10.1126/scisignal.2004102 · Cited by 41
“Indeed, studies with syndromic autism animal models showed that disease phenotypes could be rescued by therapeutic interventions in juvenile and adult mice (22, 25).”
Genes and signaling pathways involved in memory enhancement in mutant mice
Lee, Y. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-43 · Cited by 38
“Dysregulation of mTOR signaling is also associated with cognitive disorders such as tuberous sclerosis [114,115].”
BackgroundAutism and EMF? Plausibility of a pathophysiological link – Part I
Herbert, M. R., & Sage, C. (2013) · Pathophysiology · doi:10.1016/j.pathophys.2013.08.001 · Cited by 42
Neuroligin 3 Regulates Dendritic Outgrowth by Modulating Akt/mTOR Signaling
Xu, J., Du, Y.-L., Xu, J.-W., Hu, X., Gu, L.-F., Li, X., Hu, P.-H., Liao, T., Xia, Q.-Q., Sun, Q., et al. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00518 · Cited by 36
“The Tsc1 ± and Tsc2 ± mice, with decreased suppression of mTOR signaling, i.e., increased mTOR signaling, present aberrant social behaviors which could be reversed by rapamycin treatment (Goorden et al., 2007; Ehninger et al., 2008; Sato et al., 2012).”
BackgroundFDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
Lui, A., Vanleuven, J., Perekopskiy, D., Liu, D., Xu, D., Alzayat, O., Elgokhy, T., Do, T., Gann, M., Martin, R. M., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15121546 · Cited by 37
Rare deleterious mutations of the gene EFR3A in autism spectrum disorders
Gupta, A. R., Pirruccello, M., Cheng, F., Kang, H., Fernandez, T. V., Baskin, J. M., Choi, M., Liu, L., Ercan‐Sencicek, A. G., Murdoch, J. D., et al. (2014) · Molecular Autism · doi:10.1186/2040-2392-5-31 · Cited by 38
“The applicability of this approach towards ASD has been shown for the closely connected mTOR pathway in mouse models of tuberous sclerosis [41,42].”
BackgroundSilverman, J. L., & Ellegood, J. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000537 · Cited by 39
Glioma-Induced Alterations in Excitatory Neurons are Reversed by mTOR Inhibition
Goldberg, A. R., Dovas, A., Torres, D., Pereira, B., Viswanathan, A., Sharma, S. D., Mela, A., Merricks, E. M., Megino‐Luque, C., McInvale, J. J., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.12.026 · Cited by 39
The promising trajectory of autism therapeutics discovery
Silverman, J. L., & Crawley, J. N. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.12.007 · Cited by 40
Intervention in the Context of Development: Pathways Toward New Treatments
Veenstra-VanderWeele, J., & Warren, Z. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.232 · Cited by 34
“Rapamycin rescues brain and behavioral phenotypes in a mouse model of tuberous sclerosis complex, which frequently includes intellectual disability and autism spectrum disorder (Ehninger et al, 2008).”
BackgroundWaltereit, R., Banaschewski, T., Meyer‐Lindenberg, A., & Poustka, L. (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.838641 · Cited by 39
“CNTNAP2 (Arking et al. 2008; Friedman et al. 2008; Zweier et al. 2009) is another neurexin superfamily member.”
Mi, R., Ma, J., Zhang, D., Li, L., & Zhang, H. (2009) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/s1673-8527(08)60124-1 · Cited by 37
“…targeted mTOR suppression may hold promise in treating TSC in preclinical studies and clinical trials (Lee et al., 2005; Bissler et al., 2008; Ehninger et al., 2008; Paul and Thiele, 2008), in recent TSC clinical trials, lesions tended to relapse after rapamycin withdrawal (Bissler et al.,…”
BackgroundDietary interventions that reduce mTOR activity rescue autistic-like behavioral deficits in mice
Wu, J., de Theije, C. G. M., da Silva, S. L., Abbring, S., van der Horst, H. J., Broersen, L. M., Willemsen, L. E. M., Kas, M. J., Garssen, J., & Kraneveld, A. D. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.09.016 · Cited by 36
Hyperexcitability of the local cortical circuit in mouse models of tuberous sclerosis complex
Zhao, J.-P., & Yoshii, A. (2019) · Molecular Brain · doi:10.1186/s13041-019-0427-6 · Cited by 37
Yuan, H., Wu, G., Zhai, X., Lu, B., Meng, B., & Chen, J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00314 · Cited by 33
“…have shown that mTOR promotes learning and memory formation through synaptic enhancement that relies on protein synthesis (Hoeffer and Klann, 2010), and the dysregulation of mTOR has resulted in impaired learning, memory, and social behavior in mice (Banko et al., 2007; Ehninger et al., 2008).”
BackgroundAn essential role for UBE2A/HR6A in learning and memory and mGLUR-dependent long-term depression.
Bruinsma, C. F., Savelberg, S. M. C., Kool, M. J., Jolfaei, M. A., van Woerden, G. V., Baarends, W., & Elgersma, Y. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv436 · Cited by 32
Ravizza, T., Balosso, S., Aronica, E., & Vezzani, A. (2010) · CRC Press eBooks · doi:10.1201/9781420085594 · Cited by 33
Structural MRI biomarkers of shared pathogenesis in autism spectrum disorder and epilepsy
Blackmon, K. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.02.017 · Cited by 35
“In addition to seizure effects, rapamycin induces cognitive and behavioral improvements in animal models of infantile spasms [82], absence seizures [80], acquired epilepsy [87,88], and TSC [89–91]; however, timing and dosage are modifying factors.”
BackgroundNatarajan, R., Trivedi, D., & Wairkar, Y. P. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt053 · Cited by 38
Petrasek, T., Vojtechova, I., Klovrza, O., Tuckova, K., Vejmola, C., Rak, J., Sulakova, A., Kaping, D., Bernhardt, N., de Vries, P. J., et al. (2021) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-021-09357-2 · Cited by 30
Benthall, K. N., Cording, K. R., Agopyan-Miu, A. H. C. W., Wong, C. D., Chen, E. Y., & Bateup, H. S. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109511 · Cited by 35
“Indeed, Tsc1 deletion has diverse effects on intrinsic and synaptic excitability depending on the cell type studied [23, 44-55].”
BackgroundDysregulated mTORC1-Dependent Translational Control: From Brain Disorders to Psychoactive Drugs
Santini, E., & Klann, E. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00076 · Cited by 39
Genetics of antiepileptic drug resistance
Sisodiya, S. M., & Marini, C. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32832923ec · Cited by 38
Mohamed, I., Éthier, G., Goyer, I., Major, P., & Dahdah, N. (2014) · BMJ Case Reports · doi:10.1136/bcr-2014-205138 · Cited by 32
“In addition, animal models of TSC have suggested that mTOR inhibitors could have bene fi cial effects on cognitive de fi - cits 16 and on epileptogenesis.”
Tuberous sclerosis complex: a brave new world?
Ess, K. C. (2010) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32832c4ff5 · Cited by 34
mTOR and epileptogenesis in developmental brain malformations
Wong, M., & Crino, P. B. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02858.x · Cited by 32
Ouyang, T., Zhang, N., Benjamin, T., Wang, L., Jiao, J., Zhao, Y., & Chen, J. (2014) · Child s Nervous System · doi:10.1007/s00381-014-2383-x · Cited by 32
RetractedBenthall, K. N., Ong, S. L., & Bateup, H. S. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.037 · Cited by 34
“For example, in the hippocampus, loss of Tsc1 impairs mGluR-dependent long-term depression and inhibitory synapse function, leading to network hyperactivity (Bateup et al., 2011, 2013; Ehninger et al., 2008; Weston et al., 2014).”
BackgroundMechanistic Target of Rapamycin Pathway in Epileptic Disorders
Kim, J., & Lee, J. H. (2019) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2019.0027 · Cited by 38
Defining the Role of Cerebellar Purkinje Cells in Autism Spectrum Disorders
Sudarov, A. (2013) · The Cerebellum · doi:10.1007/s12311-013-0490-y · Cited by 36
“Treatment with rapamycin or RAD001 has been shown to improve survival and weight gain, to reduce seizures, and to improve some cognitive function and anatomic abnormalities [16, 20].”
Advances in understanding behavioral phenotypes in neurogenetic syndromes
Harris, J. C. (2010) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30276 · Cited by 80
“Mice with a heterozygous, inactivating mutation in the Tsc2 gene (Tsc2[þ/ ] mice) demonstrate deficits in learning and memory in the absence of neuropathology and seizures [Ehninger et al., 2008].”
BackgroundEffect of Chronic Administration of Low Dose Rapamycin on Development and Immunity in Young Rats
Lu, Z., Liu, F., Chen, L., Zhang, H., Ding, Y., Liu, J., Wong, M., & Zeng, L.-H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135256 · Cited by 32
The utility of rodent models of autism spectrum disorders
Lázaro, M. T., & Golshani, P. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000183 · Cited by 38
Gaitanis, J. N., & Donahue, J. E. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2012.12.024 · Cited by 34
Acosta, M. T., Bearden, C. E., Castellanos, F. X., Cutting, L. E., Elgersma, Y., Gioia, G. A., Gutmann, D. H., Lee, Y., Legius, E., Muenke, M., et al. (2012) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.35535 · Cited by 35
“All together, these studies showed that it is possible to reverse key cognitive deficits associated with neurodevelopmental disorders, even when the treatments are initiated in adult mice [Ehninger et al., 2008b].”
Self-citationEpilepsy in four genetically determined syndromes of intellectual disability
Leung, H. T. T., & RING, H. A. (2011) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2011.01505.x · Cited by 35
“Rapamycin reverses learning deficits in Tsc2-mutant mice (Ehninger et al. 2008), putatively through the halting of inappropriate synaptic consolidation (Ehninger et al. 2009) and the restoration of disrupted negative feedback mechanisms (Meikle et al. 2008).”
BackgroundHaji, N., Riebe, I., Aguilar‐Valles, A., Artinian, J., Laplante, I., & Lacaille, J. (2020) · Molecular Autism · doi:10.1186/s13229-020-00340-7 · Cited by 37
“Mice with global heterozygous deletion of Tsc1 [8] or Tsc2 [9] also show hippocampus-dependent spatial learning deficits.”
BackgroundInfluentialSalcedo‐Arellano, M. J., Cabal-Herrera, A. M., Punatar, R., Clark, C. J., Romney, C. A., & Hagerman, R. J. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00968-6 · Cited by 35
“deficits [126, 127] and social interactions [128].”
Deli, A., Schipany, K., Rosner, M., Höger, H., Pollak, A. J., Li, L., Hengstschläger, M., & Lübec, G. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.01.017 · Cited by 34
Crowell, B., Lee, G. H., Nikolaeva, I., Pozzo, V. D., & D’Arcangelo, G. (2015) · eNeuro · doi:10.1523/eneuro.0046-15.2015 · Cited by 32
“These rodents do not exhibit brain abnormalities, but exhibit behavioral and synaptic defects that are ameliorated by the inhibition of mTORC1 activity (Goorden et al., 2007; Ehninger et al., 2008).”
BackgroundLee, K. M., Yang, S., Choi, J., & Park, C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.523423 · Cited by 31
Early 5‐HT6 receptor blockade prevents symptom onset in a model of adolescent cannabis abuse
Berthoux, C., Hamieh, A. M., Rogliardo, A., Doucet, E. L., Coudert, C., Ango, F., Grychowska, K., Chaumont‐Dubel, S., Zajdel, P., Maldonado, R. J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910605 · Cited by 33
“These results are consistent with the role of non-physiological mTOR activation in cognitive impairment observed in genetic forms of autism spectrum disorders (ASD) and Down’s syndrome (Ehninger et al, 2008; Ehninger & Silva, 2011; Troca-Marin et al, 2012).”
BackgroundResultBiological implications of genetic variations in autism spectrum disorders from genomics studies
Zhang, Y., Liu, X., Guo, R., Xu, W., Guo, Q., Hao, C., Ni, X., & Li, W. (2021) · Bioscience Reports · doi:10.1042/bsr20210593 · Cited by 34
Self-citationModeling Social Communication Deficits in Mouse Models of Autism
Michetti, C. (2012) · Autism - Open Access · doi:10.4172/2165-7890.s1-007 · Cited by 32
Carter, A. N., Born, H. A., Levine, A. T., Dao, A. T., Zhao, A. J., Lee, W. L., & Anderson, A. E. (2017) · eNeuro · doi:10.1523/eneuro.0354-16.2017 · Cited by 32
“Hyperactive PI3K/Akt/mTOR signaling has been well characterized in epilepsy-associated memory deficits (Ehninger et al., 2008; Brewster et al., 2013; Cambiaghi et al., 2013; Trinh and Klann, 2013; Lugo et al., 2014).”
BackgroundCox, R. L., de Anda, F. C., Mangoubi, T., & Yoshii, A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00409 · Cited by 31
“For example,Tsc2 heterozygousmutantmice have impaired late longterm potentiation (L-LTP) and long-term memory (Ehninger et al., 2008).”
BackgroundLugo, J. N., Smith, G. D., Morrison, J. B., & White, J. (2013) · Learning & Memory · doi:10.1101/lm.032839.113 · Cited by 31
“Furthermore, genetic deletions of regulators of the pathway at the level of TSC1/TSC2 result in learning and memory deficits (Kwon et al. 2006; Ehninger et al. 2008).”
BackgroundYi, T., Weng, J., Siwko, S. K., Luo, J., Li, D., & Liu, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.530816 · Cited by 28
“Elevated Plus Maze Assay—The plus maze assay was performed as described previously with some modifications (41).”
BackgroundMethodInfluentialZheng, F., Kasper, L. H., Bedford, D. C., Lerach, S., Teubner, B. J. W., & Brindle, P. K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146366 · Cited by 32
“Enhanced LTP has been reported in Mecp2 transgenic mice (another Rett model) [52] and many other ASD models [43,53,54], indicating that enhanced LTP is also associated with autistic features.”
BackgroundmTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model
Polchi, A., Magini, A., Meo, D. D., Tancini, B., & Emiliani, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051474 · Cited by 31
Differential activation of the mTOR/autophagy pathway predicts cognitive performance in APP/PS1 mice
Vartak, R. S., Rodin, A., & Oddo, S. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.018 · Cited by 29
Wang, T., de Kok, L. G. C., Willemsen, R., Elgersma, Y., & Borst, J. G. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00234 · Cited by 33
“…to the absence of obvious changes in basal excitatory synaptic transmission, clear changes in longterm plasticity have been observed in Tsc2+/− Eker rats (von der Brelie et al., 2006), Tsc2+/− mice (Ehninger et al., 2008), and in the absence of Tsc1 in mice (Bateup et al., 2011; Abs et al., 2013).”
BackgroundInfluentialNeuronal mTORC1 Is Required for Maintaining the Nonreactive State of Astrocytes
Zhang, Y., Xu, S., Liang, K., Li, K., Zou, Z., Yang, C., Tan, K., Cao, X., Jiang, Y., Gao, T., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.744482 · Cited by 28
“Hyperactivation of mTORC1 by TSC1/2 deletion induces aberrant growth, proliferation and differentiation of neurons and astrocytes, resulting in neuronal dysplasia, abnormal neuronal architecture, reactive astrogliosis and seizures (27,40-42).”
BackgroundNegishi, Y., Miya, F., Hattori, A., Johmura, Y., Nakagawa, M., Ando, N., Hori, I., Togawa, T., Aoyama, K., Ohashi, K., et al. (2017) · BMC Medical Genetics · doi:10.1186/s12881-016-0363-6 · Cited by 30
mTOR plays an important role in cow's milk allergy-associated behavioral and immunological deficits
Wu, J., de Theije, C. G. M., da Silva, S. L., van der Horst, H. J., Reinders, M. T. M., Broersen, L. M., Willemsen, L. E. M., Kas, M. J., Garssen, J., & Kraneveld, A. D. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.04.035 · Cited by 28
Lin, L. (2017) · CNS Drugs · doi:10.1007/s40263-017-0431-2 · Cited by 30
Clinical features and underlying genetic causes in neonatal encephalopathy: A large cohort study
Yang, L., Chen, X. '., Liu, X., Dong, X., Ye, C., Dongli, D., Lu, Y., Lin, Y., & Zhou, W. (2020) · Clinical Genetics · doi:10.1111/cge.13818 · Cited by 32
Rapamycin for Treatment of Epilepsy: Antiseizure, Antiepileptogenic, Both, or Neither?
Wong, M. (2011) · Epiliepsy currents/Epilepsy currents · doi:10.5698/1535-7511-11.2.66 · Cited by 26
“In addition, later treatment with rapamycin in symptomatic mice can suppress or reverse seizures, as well as learning deficits, in TSC mouse models (4, 5).”
BackgroundMechanisms of translational regulation in synaptic plasticity
Sossin, W. S., & Lacaille, J. (2010) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2010.03.011 · Cited by 32
Neurodevelopmental, Psychiatric and Cognitive Aspects of Tuberous Sclerosis Complex
de Vries, P. J. (2010) · Wiley eBooks · doi:10.1002/9783527630073.ch12 · Cited by 31
Potential therapeutic approaches for Angelman syndrome
Bi, X., Sun, J., Ji, A. X., & Baudry, M. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1115837 · Cited by 29
“[123–125] Rapamycin treatment also rescued hippocampal LTP and behavioral deficits in Tsc2(±) mice.[126] Further research has shown that rapamycin treatment has beneficial effects in ASD associated”
BackgroundmTOR Inhibitors in Children: Current Indications and Future Directions in Neurology
Jeong, A., & Wong, M. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0708-8 · Cited by 27
Synaptic Plasticity in Mouse Models of Autism Spectrum Disorders
Chung, L., Bey, A. L., & Jiang, Y. (2012) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2012.16.6.369 · Cited by 31
“Heterozygotes of Tsc1 or Tsc2 mutation exhibit cognitive impairment and synaptic dysfunction in the absence of apparent neuroanatomical defects or seizures [72-75].”
BackgroundLigands for FKBP12 Increase Ca2+ Influx and Protein Synthesis to Improve Skeletal Muscle Function
Lee, C. S., Georgiou, D. K., Dagnino-Acosta, A., Xu, J., Ismailov, I. I., Knoblauch, M. A., Monroe, T. O., Ji, R., Hanna, A. D., Joshi, A., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.586289 · Cited by 30
“The macrolide rapamycin is a potent and widely used immunosuppressant that, at doses from 2 to 10 mg/kg has many beneficial physiological effects in mice (1), including increased life span (2); improved cognitive function (3); and alleviation of symptoms of cancer (4, 5), tuberous sclerosis complex (6), Alzheimer dise…”
BackgroundOverview of genetic models of autism spectrum disorders
Patel, J., Lukkes, J. L., & Shekhar, A. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.10.002 · Cited by 32
Chronic administration of theobromine inhibits mTOR signal in rats
Sugimoto, N., Katakura, M., Matsuzaki, K., Sumiyoshi, E., Yachie, A., & Shido, O. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13175 · Cited by 28
Targeted suppression of mTORC2 reduces seizures across models of epilepsy
Okoh, J. T., Mays, J., Bacq, A., Osés-Prieto, J. A., Tyanova, S., Chen, C.-J., Imanbeyev, K., Doladilhe, M., Zhou, H., Jafar‐Nejad, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42922-y · Cited by 29
“…excitation of pyramidal neurons is found in chronically injured epileptogenic neocortex 26 , (b) deletion of negative regulators of mTORC1 23,27 – 30 , or constitutive activation of mTOR 31 in excitatory neurons, leads to spontaneous seizures, (c) selective optogenetic-mediated stimulation…”
Advanced Pharmacotherapy Evidenced by Pathogenesis of Autism Spectrum Disorder
Lee, Y. J., Oh, S. H., Park, C., Hong, M., Lee, A. R., Yoo, H. J., Shin, C. Y., Cheon, K.-A. A., & Bahn, G. H. (2014) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2014.12.1.19 · Cited by 29
Major, P. (2011) · Aging · doi:10.18632/aging.100298 · Cited by 25
“In addition, animal models of TSC have suggested that mTOR inhibitors could have beneficial effects on cognitive deficits [15] and on epileptogenesis [16].”
BackgroundCôté, V., Lalancette, È., Knoth, I. S., Côté, L., Agbogba, K., Vannasing, P., Major, P., Barlaam, F., Michaud, J. L., & Lippé, S. (2020) · Brain Research · doi:10.1016/j.brainres.2020.147205 · Cited by 32
Autophagy in neural stem cells and glia for brain health and diseases
Nagayach, A., & Wang, C. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.382227 · Cited by 32
“Apparently, pharmacological therapy using rapamycin has been moderately successful in restoring behavioral and cognitive symptoms in various neurodevelopment disorders, like ASD (Wang et al., 2023) and tuberous sclerosis complex (Ehninger et al., 2008; Sato et al., 2012).”
Amygdala Regulation of Fear and Emotionality in Fragile X Syndrome
Olmos-Serrano, J. L., & Corbin, J. G. (2011) · Developmental Neuroscience · doi:10.1159/000329424 · Cited by 27
New therapeutic options for autism spectrum disorder: experimental evidences
Peñagarikano, O. (2015) · Experimental Neurobiology · doi:10.5607/en.2015.24.4.301 · Cited by 24
“The traditional concept that abnormalities occurring during brain development are permanent and thus neurodevelopmental disorders irreversible, has been challenged in the past few years by studies on mouse models of neurodevelopmental disorders including Rett syndrome [19], fragile X syndrome [20], neurofibromatosis t…”
BackgroundThe Small GTPase Rheb Affects Central Brain Neuronal Morphology and Memory Formation in Drosophila
Brown, H. L. D., Kaun, K. R., & Edgar, B. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044888 · Cited by 25
Saliba, S. W., Vieira, É. L. M., Santos, R. P. D. M., Candelario‐Jalil, E., Fiebich, B. L., Vieira, L. B., Teixeira, A. L., & de Oliveira, A. C. P. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0793-x · Cited by 25
“Low concentrations of rapamycin can improve learning and memory [31, 32].”
A brain proteomic investigation of rapamycin effects in the Tsc1 +/− mouse model
Wesseling, H., Elgersma, Y., & Bahn, S. (2017) · Molecular Autism · doi:10.1186/s13229-017-0151-y · Cited by 26
“Deficits in consolidating short- and long-term memory and spatial navigation have been shown to be impaired in Tsc1 and Tsc2 mice and were reversed by rapamycin treatment in Tsc2 mice [24].”
BackgroundMammalian Target of Rapamycin at the Crossroad Between Alzheimer’s Disease and Diabetes
Liang, H., Nie, J., Skike, C. E. V., Valentine, J. M., & Orr, M. E. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-3540-2_10 · Cited by 26
Dysregulated translational control in brain disorders: from genes to behavior
Wiebe, S. A., Nagpal, A., & Sonenberg, N. (2020) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.05.005 · Cited by 24
Translational research: Rett syndrome and tuberous sclerosis complex
Khwaja, O., & Şahin, M. (2011) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32834c9251 · Cited by 23
Role of the PTEN signaling pathway in autism spectrum disorder
Lv, J., Cheng, T., Qiu, Z., & Zhou, W. (2013) · Neuroscience Bulletin · doi:10.1007/s12264-013-1382-3 · Cited by 26
Behavior in a Drosophila Model of Fragile X
McBride, S. M. J., Bell, A. J., & Jongens, T. A. (2011) · Results and problems in cell differentiation · doi:10.1007/978-3-642-21649-7_6 · Cited by 25
mTOR and Epileptogenesis in Developmental Brain Malformations
Wong, M., & Crino, P. B. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780199746545.003.0065 · Cited by 29
Sato, A., & Ikeda, K. (2021) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2021.08.005 · Cited by 25
“98 Biological Psychiatry: Global Open Science April 2022; 2:95–105 w treatment reversed ASD-related behavior (41,43) and cognitive deficits (40) through mTORC1 inhibition.”
BackgroundResultmTOR-Dependent Spine Dynamics in Autism
Chaudry, S., & Vasudevan, N. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.877609 · Cited by 24
A Brain Region-Specific Predictive Gene Map for Autism Derived by Profiling a Reference Gene Set
Kumar, A., Swanwick, C. C., Johnson, N., Menashe, I., Basu, S. N., Bales, M. E., & Banerjee‐Basu, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028431 · Cited by 26
Does any drug to treat cancer target mTOR and iron hemostasis in neurodegenerative disorders?
Farshbaf, M. J., & Ghaedi, K. (2016) · BioMetals · doi:10.1007/s10534-016-9981-x · Cited by 22
“Mice with tuberous sclerosis showed cognition deficits and high mTOR activity but using of rapamycin, as the specific inhibitor for mTOR, revealed cognition and synaptic abnormalities (Ehninger et al. 2008).”
BackgroundNeuropsychological Attention Skills and Related Behaviours in Adults with Tuberous Sclerosis Complex
Tierney, K. M., McCartney, D. L., Serfontein, J., & de Vries, P. J. (2010) · Behavior Genetics · doi:10.1007/s10519-010-9423-4 · Cited by 26
“The molecular model is supported by evidence of learning and behavioural deficits in TSC animal models in the absence of structural brain lesions or seizures (de Vries and Howe 2007; Ehninger et al. 2008; Goorden et al. 2007; Waltereit et al. 2006, 2011; Ehninger and Silva 2011 ).”
MethodWang, H., Chang, N.-C., Weng, Y.-H., & Yeh, T. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.01.010 · Cited by 26
Current Review in Basic Science: Animal Models of Focal Cortical Dysplasia and Epilepsy
Nguyen, L. H., & Bordey, A. (2022) · Epiliepsy currents/Epilepsy currents · doi:10.1177/15357597221098230 · Cited by 21
Muñoz, A. R., Pacheco, C. R., Aguayo, L. G., & Opazo, C. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.019 · Cited by 24
Potential for treatment of severe autism in tuberous sclerosis complex
Gipson, T., Gerner, G. J., Wilson, M. A., Blue, M. E., & Johnston, M. V. (2013) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v2.i3.16 · Cited by 23
Genetics and neuropsychiatric disorders: treatment during adulthood
Ehninger, D., & Silva, A. J. (2009) · Nature Medicine · doi:10.1038/nm0809-849 · Cited by 21
Self-citationRandell, E., McNamara, R. L., Davies, D. M., Owen-Jones, E., Kirby, N., Angel, L., Drew, C., Cannings-John, R. L., Smalley, M., Saxena, A., et al. (2016) · Trials · doi:10.1186/s13063-016-1446-6 · Cited by 23
“Published findings from the Tsc2 study [9] came at a time which served to reinforce interest in the neurocognitive trials in humans.”
BackgroundShen, W., Lu, K., Wang, J., Wu, A., & Yue, Y. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5700 · Cited by 204
Lana, D., Russo, J. D., Mello, T., Wenk, G. L., & Giovannini, M. G. (2016) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.11.006 · Cited by 24
“Indeed, transgenic mice with constant activation of the hippocampal mTOR pathway (Ehninger et al., 2008; Goorden, van Woerden, van der Weerd, Cheadle, & Elgersma, 2007), and patients with tuberous sclerosis who have increase of mTORC1 activity, show memory deficits (Ehninger et al.”
BackgroundInfluentialDenbow, D. M., & Cline, M. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407160-5.00021-x · Cited by 23
Cracking novel shared targets between epilepsy and Alzheimer’s disease: need of the hour
Garg, N., Joshi, R., & Medhi, B. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0064 · Cited by 23
Moavero, R., Mühlebner, A., Luinenburg, M. J., Craiu, D., Aronica, E., & Curatolo, P. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2020.107713 · Cited by 27
Henzel, K. S., Ryan, D. P., Schröder, S., Weiergräber, M., & Ehninger, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-03158-1 · Cited by 24
Self-citation
Metadata
- Authors
- Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J.
- Affiliations
- University of California, Los Angeles (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Silva, Alcino J
- Venue
- Nature Medicine
- Published
- 2008-06-22
- Volume
- 14
- Issue
- 8
- Pages
- 843-848
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC2664098
- OpenAlex
- W1989779456
- Cited by
- 882
- References
- 30
- Citations by year
- 2026: 22 · 2025: 24 · 2024: 23 · 2023: 28 · 2022: 31 · 2021: 40 · 2020: 48 · 2019: 37 · 2018: 40 · 2017: 46 · 2016: 55 · 2015: 76 · 2014: 61 · 2013: 73 · 2012: 90
- FWCI
- 44.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Autism Speaks (AS1862)
- National Institute of Neurological Disorders and Stroke (R01NS038480, P01NS024279)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- tuberous sclerosis complex, mTOR signaling, hippocampal long-term potentiation, hippocampus-dependent learning, spatial learning deficits, contextual discrimination, cognitive impairment, rapamycin, mTOR inhibitors, synaptic plasticity, autism spectrum disorder, intellectual disability
- MeSH terms
- Tuberous Sclerosis Complex 2 Protein, Animals, Behavior, Animal, Cognition Disorders, Female, Heterozygote, Hippocampus, Learning, Male, Mice, Inbred C57BL, Protein Kinases, Tuberous Sclerosis, Signal Transduction, Sirolimus, Tumor Suppressor Proteins, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.